Jump to content
International Collaboration For Dog Health And Welfare. Join Us.

    Sentinel Biomedical is a pioneering comparative health company committed to research and scientific innovation. The company’s primary focus is investigating canine cancers and identifying biological changes and environmental influences that may be shared with human cancers, making canines true watchdogs in the area of human health.

     

    harmonization-of-genetic-testing-for-dogs-2-12-2018.png

    Sentinel Biomedical is a proud sponsor of IPFD's Harmonization of Genetic Testing for Dogs Initiative.

     

     

     


    About Us:

    By taking a comparative approach to research, the company aspires to accelerate the pace of cancer-related discoveries leading to improved diagnosis, treatment and patient outcomes. Sentinel Biomedical created the world’s first and most rapid and reliable early detection system for canine bladder cancer/TCC/UC, allowing for more timely therapeutic intervention. The company continues to develop innovative cancer detection products with forensic level sensitivity, supported by robust research, proven science and leading genetics and oncology experts.

     

    Headquartered at North Carolina State University’s Centennial Biomedical Campus in Raleigh, N.C., the company was formed in 2015 by Matthew Breen, PhD CBiol FRSB and a team of highly experienced researchers.


    Designation:
    For Profit Company, Academic Institution





×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.